Eligibility criteria in RCTs of anti-VEGF therapy for diabetic macular edema: A systematic review

This publication has 54 references indexed in Scilit:

• Efficacy and Safety of Brolucizumab for Diabetic Macular Edema
  JAMA Ophthalmology, 2023
• Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries
  Ophthalmology and Therapy, 2023
• Representation of Race and Ethnicity in Randomized Clinical Trials of Diabetic Macular Edema and Retinal Vein Occlusion Compared to 2010 US Census Data
  JAMA Ophthalmology, 2022
• KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema
  American Journal of Ophthalmology, 2022
• Systemic risk factors contribute differently to the development of proliferative diabetic retinopathy and clinically significant macular oedema
  Diabetologia, 2020
• Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study
  Graefe's Archive for Clinical and Experimental Ophthalmology, 2020
• Intravitreal Ranibizumab Therapy for Diabetic Macular Edema in Routine Practice: Two-Year Real-Life Data from a Non-interventional, Multicenter Study in Germany
  Diabetes Therapy, 2018
• Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice
  American Journal of Ophthalmology, 2018
• A Prospective Randomized Trial of Intravitreal Bevacizumab Versus Ranibizumab for the Management of Diabetic Macular Edema
  American Journal of Ophthalmology, 2013
• Persistent diabetic macular edema is associated with elevated hemoglobin A1c
  American Journal of Ophthalmology, 2005